Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.48 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSH | P09668 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL332255 | 0.88 | SRR (0.47) | TAAR1MEN1KMT2ACYP2D6CYP1A2 | |
| SCHEMBL12630152 | 0.84 | SMN1; SMN2 (0.46) | TAAR1MEN1KMT2ACTSKCTSL | |
| SCHEMBL10590311 | 0.84 | MEN1 (0.41) | TAAR1MEN1KMT2ACTSKCTSL | |
| SCHEMBL7312539 | 0.83 | PPARG (0.41) | TAAR1MEN1KMT2AMAOACYP2A6 | |
| SCHEMBL18085416 | 0.83 | EPHX1 (0.48) | TAAR1MEN1KMT2ASIGMAR1SLC6A2 | |
| SCHEMBL11082687 | 0.82 | CYP19A1 (0.44) | TAAR1MEN1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL16021181 | 0.82 | PPARG (0.42) | TAAR1MEN1KMT2ACTSKCTSL | |
| SCHEMBL2554498 | 0.81 | TSHR (0.47) | TAAR1MEN1KMT2AEPHX1CTSB | |
| SCHEMBL2918968 | 0.81 | SIGMAR1 (0.48) | TAAR1MEN1KMT2ASIGMAR1SLC6A2 | |
| SCHEMBL15802699 | 0.79 | EPHX1 (0.56) | TAAR1MEN1KMT2ASIGMAR1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1493747-B1 | PROCESS FOR PRODUCING MODIFIED PEPTIDE | DAIICHI SANKYO CO LTD (JP) | 2012-12-19 | — | — | EP | claimed |
| US-3944590-A | ALKYL PHENYL CARBONATES | CIBA-GEIGY CORPORATION (US) | 1976-03-16 | — | — | US | claimed |
| CN-115704995-A | Curable composition, cured film and application thereof, method for producing cured film, and polymer | JSR株式会社 | 2023-02-17 | — | — | CN | disclosed |
| CN-115433591-A | Liquid crystal aligning agent, liquid crystal alignment film, liquid crystal element, polymer and method for producing same | JSR株式会社 | 2022-12-06 | — | — | CN | disclosed |
| CN-115197719-A | Liquid crystal aligning agent, liquid crystal alignment film, liquid crystal element, and method for producing same | JSR株式会社 | 2022-10-18 | — | — | CN | disclosed |
| US-20180065921-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2018-03-08 | — | — | US | disclosed |
| CN-107636056-A | Multifunctional optical high transparency film and its production method | 艾兰德高分子工业有限公司 | 2018-01-26 | — | — | CN | disclosed |
| EP-1493747-B1 | PROCESS FOR PRODUCING MODIFIED PEPTIDE | DAIICHI SANKYO CO LTD (JP) | 2012-12-19 | — | — | EP | disclosed |
| US-7799775-B2 | such as 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-ylpiperazin-1-yl)propylthio]-3H-thieno[2,3-d]pyrimidin-4-one, having serotonin receptor modulatory activity, used for treating irritable bowel syndrome | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| US-20070197551-A1 | Pyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | disclosed |
| EP-1724267-A1 | PYRIMIDINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2006-11-22 | — | — | EP | disclosed |
| US-4086221-A | SERUM CALCIUM REDUCING ACTIVITY | TOYO JOZO KABUSHIKI KAISHA (JA) | 1978-04-25 | — | — | US | disclosed |
| US-4063025-A | PROPHYLAXIS, ANTIASTHMATIC | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) | 1977-12-13 | — | — | US | disclosed |
| US-4041161-A | ANTIBIOTICS | CIBA-GEIGY CORPORATION (US) | 1977-08-09 | — | — | US | disclosed |
| US-4015000-A | 6-Acylamino-penam-3-carboxylic and 7-acylamino-3-cephem-4-carboxylic acids | CIBA-GEIGY CORPORATION (US) | 1977-03-29 | — | — | US | disclosed |
| US-3994871-A | Process for the manufacture of peptides containing cystine | CIBA-GEIGY CORPORATION (US) | 1976-11-30 | — | — | US | disclosed |
| US-3956260-A | ANTIINFLAMMATORY | CIBA-GEIGY CORPORATION (US) | 1976-05-11 | — | — | US | disclosed |
| US-3954802-A | Substituted-ureido derivatives of penam 3-carboxylic acid and cephem 4-carboxylic acid | CIBA-GEIGY CORPORATION (US) | 1976-05-04 | — | — | US | disclosed |
| US-3944590-A | ALKYL PHENYL CARBONATES | CIBA-GEIGY CORPORATION (US) | 1976-03-16 | — | — | US | disclosed |
| US-3934008-A | PEPTIDES, HYPOCALCAEMIC | CIBA-GEIGY CORPORATION (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197551-A1 | Pyrimidine derivatives | HTR3B, HTR3A, HTR1A | TAAR1 297/4885MEN1 3933/4885KMT2A 3783/4885 |
| US-20180065921-A1 | METHODS OF TREATING FIBROSIS | MMP1, MMP8, FABP2 | TAAR1 3882/4885MEN1 4490/4885KMT2A 3951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.